Acute complications of Sickle Cell Anemia

Introduction & Pathophysiology

• Autosomal recessive hemoglobinopathy caused by point mutation (A-T) at sixth codon of $\beta$-globin gene (chromosome 11).
• Amino acid substitution: valine replaces glutamic acid.
• Deoxygenated HbS polymerizes, dictating cellular alterations and rigid, sickled red blood cell (RBC) forms.
• Central event: Vaso-occlusion inducing microvascular ischemia-reperfusion injury.
• Multifactorial pathogenesis involves hemolysis-associated nitric oxide depletion, chronic inflammation, oxidative stress, impaired fibrinolysis, hyperviscosity, and platelet/leukocyte activation.
• Acute crises manifest with severe hematological, infectious, and vaso-occlusive presentations demanding rapid intervention.

Vaso-Occlusive Event (VOE) / Pain Crisis

Pathogenesis & Clinical Presentation

• Cardinal clinical feature; unremitting discomfort.
• Initiated by blood flow disruption in microvasculature via sickled RBCs and cellular elements, inducing tissue ischemia.
• Common sites: Chest, abdomen, extremities, long bones, sternum, ribs, spine, pelvis.
• Dactylitis (hand-foot syndrome): Symmetric/unilateral painful swelling of hands/feet; common in children <3 years.
• Precipitating triggers: Physical stress, infection, dehydration, hypoxia, acidosis, cold exposure, prolonged swimming.
• Incidence: Average 0.8 events/year prompting medical evaluation in SCD-SS.
• Risk factors: High baseline hemoglobin, low hemoglobin F, nocturnal hypoxemia, asthma.

Differentiating Bone Infarction vs. Osteomyelitis

Feature	Bone Infarction (VOE)	Osteomyelitis
History	Prior similar pain episodes common	Previous history unusual.
Clinical	Multiple sites involved simultaneously	Often single site involved.
Erythrocyte Sedimentation Rate	Normal to low	Elevated.
Blood Culture	Negative	Positive (Salmonella, Staphylococcus).
Magnetic Resonance Imaging	Abnormal	Abnormal.
Bone Scan (99mTc-diphosphonate)	Abnormal	Abnormal.
Marrow Scan (99mTc-colloid)	Decreased uptake	Normal uptake.
Recovery	Spontaneous	Requires appropriate antibiotic therapy.

Phases of Sickle Cell Pain

Phase	Characteristics
I. Baseline	No pain; no comfort measures.
II. Prepain	Prodromal signs (yellow eyes, fatigue). Caregivers increase fluids to prevent escalation.
III. Pain Starting Point	Mild ache. Mild analgesics (ibuprofen/acetaminophen) initiated. Normal activities maintained.
IV. Pain Acceleration	Pain escalates (mild to moderate); spreads to multiple areas. Activity decreases. Stronger oral analgesics combined with non-pharmacologic comfort (heat, distraction).
V. Peak Pain Experience	Severe, incapacitating pain (“stabbing,” “excruciating”). Emergency department evaluation sought for stronger analgesics.
VI. Postinfarctive/Inflammatory	Fever, severe steady pain, swelling, joint effusions. Elevated WBC, C-reactive protein, LDH, CPK.
VII. Resolving/Recovery	Hemoglobin/reticulocytes return to baseline. Decreased dense RBCs and irreversibly sickled cells.

Acute Management Protocol

Home Management

• Initiate nonsteroidal anti-inflammatory drugs (NSAIDs) (ibuprofen) and/or acetaminophen.
• Add oral opioids for escalating pain (codeine for mild; oxycodone/hydrocodone/morphine for moderate).
• Supportive measures: Heating pad, fluids, stool softeners/laxatives (prevent opioid constipation).

Emergency Department / Acute Care

• Rapid triage and administration of analgesics.
• Administer IV ketorolac tromethamine (NSAID) and IV opioids for severe pain.
• Maintain euvolemia; use IV normal saline bolus strictly for identified dehydration/decreased oral intake.
• Avoid aggressive IV hydration unless dehydrated; does not relieve pain.

Inpatient Management

• Scheduled IV opioids; avoid “as-needed” dosing.
• Patient-controlled analgesia (PCA) pump for inadequately controlled pain.
• Adjuvant therapies: Long-acting sustained-release morphine.
• Supportive care: Incentive spirometry (prevents Acute Chest Syndrome), bowel regimen, antihistamines for pruritus, serial compression devices/LMWH for VTE prophylaxis (age $\ge$ 12).
• Transition to oral NSAIDs and opioids upon improvement.
• Investigational: Recombinant ADAMTS13, IV immunoglobulin, inhaled nitrous oxide.
• Preventive: Crizanlizumab (anti-P-selectin antibody).

Acute Chest Syndrome (ACS)

Etiology & Risk Factors

• Leading cause of death; second most common cause of hospitalization.
• Causes: Infection (Mycoplasma, Chlamydia, S. pneumoniae, Parvovirus B19), fat embolization from infarcted marrow, hypoventilation, iatrogenic overhydration.
• Frequent preceding event: Systemic opioid treatment for VOE resulting in hypoventilation.
• Incidence: Peak in 2- to 5-year-olds (25 events/100 patient-years).
• Risk factors: Asthma, high hemoglobin, elevated WBC count.

Clinical & Laboratory Findings

• Definition: New pulmonary radiodensity accompanied by fever, chest pain, tachypnea, cough, hypoxemia, wheezing.
• Rapid progression from simple infiltrate to extensive bilateral consolidation and pleural effusion.
• Fat embolism syndrome features: Rapid respiratory distress, altered mental status, petechial rash.
• Laboratory: Elevated WBC, sudden hemoglobin drop (1.5 g/dL below baseline), subsequent thrombocytosis.

Management Strategy

Respiratory & Hemodynamic Support

• Continuous pulse oximetry; frequent respiratory assessments.
• Supplemental oxygen for hypoxia (drop in pulse oximetry by 4% over baseline, or values <90%).
• IV/oral fluids kept at maintenance; strict avoidance of overhydration.
• Regular incentive spirometry (10-12 breaths every 2 hours).
• Chest physiotherapy and mechanical ventilation as needed.

Pharmacotherapy & Transfusion

• Empirical Antibiotics: Broad-spectrum IV cephalosporin combined with oral macrolide (erythromycin/azithromycin) targeting atypical bacteria.
• Bronchodilators: Indicated for reactive airway disease history or active wheezing.
• Corticosteroids: Beneficial for severe ACS/asthma component; caution required due to rebound VOE pain upon discontinuation.
• Pain control: Optimize analgesia to prevent splinting; avoid oversedation causing hypoventilation.
• Transfusion:
  • Simple RBC transfusion (10-15 cm3/kg); target maximum post-transfusion Hb $\le$ 10 g/dL.
  • Exchange transfusion: Indicated for severe hypoxemia, respiratory distress, or failure to improve with simple transfusion.

Neurological Complications (Acute Overt Stroke)

Pathophysiology & Presentation

• Predominantly ischemic in children; hemorrhagic stroke incidence increases in older children/adults.
• Pathogenesis: Chronic endothelial injury by sickled RBCs causes intimal proliferation and luminal narrowing.
• Primary locations: Distal internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA).
• Infarction mechanism: In situ occlusion, distal embolization, or perfusional deficit in watershed zones.
• Clinical presentation: Acute focal neurological deficit lasting >24 hours, hemiparesis, slurred speech, altered consciousness, seizures.
• Differential diagnosis: Posterior reversible encephalopathy syndrome (PRES), cerebral venous thrombosis, fat embolism syndrome.

Diagnostic Imaging

• Emergent evaluation by neurology/hematology.
• Non-contrast Head CT: Rapidly excludes intracranial hemorrhage.
• Brain MRI (diffusion-weighted): Highly sensitive for early ischemia (abnormal within 1 hour).
• MR Angiography (MRA) / MR Venography: Identifies cerebral vasculopathy or venous thrombosis; secondary to acute stabilization.

Acute Management

• Maintain oxygen saturation >96%.
• Rapid simple blood transfusion within 2 hours of presentation.
  • Goal: Elevate hemoglobin to maximum 10 g/dL. Strictly avoid exceeding 10 g/dL to prevent hyperviscosity-induced cerebral ischemia.
• Exchange transfusion (manual or automated erythrocytapheresis) must follow promptly to reduce HbS percentage to <30%.
• Supportive therapy: Avoid hypotension; maintain euthermia.

Splenic Sequestration Crisis

Pathogenesis & Clinical Features

• Life-threatening complication; primarily affects infants and children aged 6 months to 2 years (SCD-SS).
• Can occur throughout adulthood in SCD-SC and SCD-S${\beta }^{+}$-thalassemia.
• Pathophysiology: Massive pooling and trapping of blood within the spleen.
• Triggers: Spontaneous, fever, bacteremia, viral infections (e.g., Parvovirus B19).
• Presentation: Rapid splenic enlargement, left-sided abdominal pain, pallor, fatigue.
• Hemodynamic compromise: Precipitous hemoglobin decline (often <3 g/dL), hypovolemic shock, death.
• Laboratory: Marked reticulocytosis, nucleated RBCs, decreasing WBC and platelet counts.

Management & Prevention

• Continuous cardiovascular monitoring.
• Fluid resuscitation: Isotonic normal saline bolus (10-20 cm3/kg) for hypovolemia.
• RBC Transfusion:
  • Small aliquots (5 mL/kg) administered carefully.
  • Goal: Target post-transfusion Hb 8 g/dL to prevent hypovolemia.
  • Caution: Transfusion aborts RBC trapping; sequestered cells release back into circulation (autotransfusion). High transfusion volumes risk severe hyperviscosity syndrome.
• Secondary Prevention:
  • Recurrence rate 65%, usually within 6 months.
  • Prophylactic splenectomy post-recovery is the definitive preventive strategy.
  • Chronic transfusion therapy utilized temporarily in children <2 years to delay splenectomy.

Transient Pure Red Cell Aplasia (Aplastic Crisis)

Etiology & Presentation

• Temporary cessation of RBC production persisting 7-14 days.
• Pathogenesis: Almost invariably triggered by Human Parvovirus B19 infection. Virus directly infects Colony-Forming Unit-Erythroid progenitors, arresting maturation.
• Presentation: Gradual onset of profound anemia; fever.
• Laboratory: Severe reticulocytopenia; sharp decrease in marrow nucleated RBCs. WBC and platelet counts unaffected.
• Associated complications: Pain, splenic sequestration, ACS, stroke, glomerulonephritis.
• Diagnosis: Parvovirus PCR assay strictly superior to IgM/IgG serology.

Management Protocol

• Spontaneous recovery heralded by nucleated RBC appearance and subsequent robust reticulocytosis.
• Hemodynamic monitoring.
• Conservative RBC transfusion indicated only for hemodynamic instability or concurrent severe illness.
  • Target post-transfusion hemoglobin maximum 9-10 g/dL.
• Strict isolation precautions: Highly contagious. Risk of nosocomial spread and danger to pregnant caregivers (hydrops fetalis).
• Monitor siblings with SCD via CBC, reticulocyte count, and Parvovirus PCR.

Priapism

Classification & Pathophysiology

• Unwanted, sustained, painful penile erection.
• Mean onset age 15 years; affects males across all sickle genotypes.
• Pathophysiology: Low-flow state; venous stasis caused by RBC sickling in corpora cavernosa.
• Patterns:
  • Prolonged: Lasting >4 hours.
  • Stuttering: Brief episodes <3 hours; cluster frequently and herald prolonged events.
• Complications: Irreversible ischemic injury, high risk of erectile dysfunction (impotence).

Acute Management

Conservative & Pharmacologic

• Home interventions: Warm baths, oral analgesics, increased oral hydration, brief aerobic exercise, oral pseudoephedrine.
• Emergency evaluation mandated for episodes lasting >2 hours.
• ER treatment: Intravenous hydration, parenteral opioid analgesia.
• Investigational: Inhaled nitrous oxide (maximum 60%) for rapid detumescence.

Surgical & Transfusion

• Prolonged episodes (>4 hours) require urgent urological consultation.
• Aspiration of blood from corpus cavernosum.
• Irrigation with dilute epinephrine (1:1,000,000) or alpha-adrenergic agent (phenylephrine) to induce sustained detumescence.
• Simple or exchange blood transfusion utilized if surgical management fails; however, detumescence may delay up to 24 hours post-transfusion, risking acute neurological events.

Fever and Serious Bacterial Infections (Bacteremia)

Pathogenesis (Functional Asplenia)

• Medical emergency with high mortality rate.
• Splenic dysfunction evident by 6 months; complete functional asplenia by 5 years.
• Profound susceptibility to encapsulated organisms: Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis, and Salmonella spp..

Clinical Risk Factors for Acute Complications in Febrile Children

Parameter	High-Risk Indicators
Clinical Exam	Seriously ill appearance, meningeal signs, enlarging spleen.
Hemodynamics	Hypotension (Systolic BP <70 mm Hg + 2 $\times$ age in years). Poor perfusion (Capillary refill >4 seconds).
Vitals	Temperature >40.0°C (104°F). Hypoxia.
Laboratory	WBC count >30,000/mm${}^3$ or <5,000/mm${}^3$. Platelet count <100,000/mm${}^3$. Hemoglobin <5.0 g/dL.
History	Prior pneumococcal sepsis, severe pain, acute chest syndrome presence, lack of prophylactic antibiotics/immunizations.

Acute Management

• Rapid clinical evaluation, CBC with differential, reticulocyte count, and multiple blood cultures.
• Chest radiograph indicated for all children <3 years or older children with respiratory symptoms.
• Lumbar puncture for young infants (<2-3 months) or older children displaying meningeal signs.
• Prompt initiation of broad-spectrum IV antimicrobials (e.g., ceftriaxone, ampicillin, or third-generation cephalosporin) targeting encapsulated pathogens.
• Hospital admission for 24 hours is standard for IV antimicrobial therapy and observation.
• Outpatient management considered only for lowest-risk children post-IV ceftriaxone dose, ensuring continuous blood culture monitoring and reliable follow-up.
• Note: Patients receiving ceftriaxone must be monitored for rapid, life-threatening immune hemolysis.
• If Salmonella or S. aureus bacteremia develops, perform MRI to evaluate for osteomyelitis.